EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Global Blood Therapeutics's Enterprise Value is $4,762.7 Mil.
Global Blood Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 was $-251.3 Mil. Therefore, Global Blood Therapeutics's EV-to-FCF for today is -18.95.
The historical rank and industry rank for Global Blood Therapeutics's EV-to-FCF or its related term are showing as below:
GBT'
s EV-to-FCF Range Over the Past 10 Years
Min: -23.22 Med: -10.43 Max: -6.04
Current: -18.95
During the past 9 years, the highest EV-to-FCF of Global Blood Therapeutics was -6.04. The lowest was -23.22. And the median was -10.43.
GBT's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 8.36
vs GBT: -18.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Global Blood Therapeutics's EV-to-FCF
For the Biotechnology subindustry, Global Blood Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Global Blood Therapeutics's EV-to-FCF Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Global Blood Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Global Blood Therapeutics's EV-to-FCF falls into.
Global Blood Therapeutics's current Enterprise Value is $4,762.7 Mil.
Global Blood Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-251.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Global Blood Therapeutics (NAS:GBT) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Global Blood Therapeutics's PE Ratio for today is calculated as:
Global Blood Therapeutics's share price for today is $68.49.
Global Blood Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Global Blood Therapeutics EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Global Blood Therapeutics's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Global Blood Therapeutics (Global Blood Therapeutics) Business Description
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GBT has been successfully added to your 